Deferiprone Helps In Treating Iron Overload By Binding To Iron And Removing It From The Blood22/9/2022 Deferiprone is a chelating agent that traps and removes excess iron from blood transfusions. It can help patients undergoing blood transfusions to feel better, it also poses risks. It can cause neutropenia or agranulocytosis. Moreover, it can harm a fetus if administered to a pregnant woman. Deferiprone is a chelation agent with a high affinity for the ferric ion. It forms 3:1 complexes with ferric ions and is stable across a wide pH range. It has cytotoxicity as high as 10 times that of maltol in HL-60 and HSC-2 cell lines. It may be used to treat a variety of inflammatory and chronic diseases. Deferiprone is a bioactive compound that traps and removes excess iron in blood transfusions. The drug works by improving the membrane fluidity of red blood cells. It improves cellular structure and functions and reduces the levels of redox active iron, which catalyzes free radical reactions. It also improves hemoglobin content. The structure of Deferiprone is dominated by a triad of three-hydroxypyridinone (HP) groups. HPs with this structure are highly efficient chelating agents as they do not need a high chelating agent concentration. Clinical formulations of chelating agents containing HPs are important for this reason. However, it is important to separate the labelled conjugate from the unlabelled form of the drug. Large amounts of the unlabelled compound may overwhelm the target receptors in vivo. Blood transfusions may lead to an excess of iron in the body, particularly if the patient has a blood disorder that causes anemia. High levels of iron in the blood can lead to many problems, including heart failure, liver damage, and diabetes. High levels of iron may also affect children's growth. Deferiprone belongs to a group of drugs known as iron chelators that can treat excess iron in blood. Deferiprone is eliminated from the body through the kidneys. The first 24 hours after oral administration, about 75 to 90 percent of the drug is recovered from the urine. It is also excreted in feces to a lesser extent. The half-life of deferiprone is 2 to 3 hours. Deferiprone is a prescription medicine that is usually taken three times daily. It is not recommended for use by anyone younger than 18 years of age. Deferiprone is taken with food or water. It can cause stomach upset if not taken properly. It is important to take effective birth control while taking the medication and for up to six months after stopping it. Despite this potential risk, Deferiprone is a very efficient and important chelating agent. While it has been shown to cause neutropenia, it is important to understand the causes of agranulocytosis and how deferiprone can reduce the risk of these side effects. A pregnant woman should not take Deferiprone during her pregnancy, as it may harm the fetus. While the drug is known to cause adverse pharmacological effects in animals, there are no human studies confirming the effects of this drug on fetal development. It is important for pregnant women to be informed of this potential fetal risk and to use effective contraception during and after treatment with deferiprone. When blood transfusions contain high amounts of iron, the body cannot effectively remove this excess iron. It accumulates in the organs. If this is left untreated, hemochromatosis may develop.
0 Comments
Leave a Reply. |
Categories
All
|